Depression - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Depression - Pipeline Review, H1 2019’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Depression

- The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Depression therapeutics and enlists all their major and minor projects

- The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Depression

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acadia Pharmaceuticals Inc

Adamed Sp zoo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Alkermes Plc

Allergan Plc

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Angelini Group ...

Acadia Pharmaceuticals Inc

Adamed Sp zoo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Alkermes Plc

Allergan Plc

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Angelini Group

Atai Life Sciences AG

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Azevan Pharmaceuticals Inc

Bionomics Ltd

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calico LLC

Celgene Corp

Cellix Bio Pvt Ltd

Celon Pharma SA

Cerecor Inc

Clera Inc

Clexio Biosciences Ltd

Delpor Inc

Denovo Biopharma LLC

Douglas Pharmaceuticals Ltd

Eisai Co Ltd

Eli Lilly and Co

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

GliaCure Inc

H. Lundbeck AS

Hua Medicine Shanghai Ltd

Impel NeuroPharma Inc

Intas Pharmaceuticals Ltd

Intra-Cellular Therapies Inc

Jiangsu Nhwa Pharmaceutical Corp Ltd

Jina Pharmaceuticals Inc

Johnson & Johnson

KemPharm Inc

Kissei Pharmaceutical Co Ltd

Krenitsky Pharmaceuticals Inc

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Luye Pharma Group Ltd

Mapi Pharma Ltd

Mapreg SAS

MedinCell SA

Medlab Clinical Ltd

Meta-IQ ApS

Mitsubishi Tanabe Pharma Corp

Navitor Pharmaceuticals Inc

Neuralstem Inc

Neurocrine Biosciences Inc

Neurolixis Inc

NeuroNascent Inc

Nippon Chemiphar Co Ltd

Novartis AG

Omeros Corp

Otsuka Holdings Co Ltd

Pfizer Inc

Protagenic Therapeutics Inc

Relmada Therapeutics Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Shenox Pharmaceuticals LLC

SK Biopharmaceuticals Co Ltd

Sosei Heptares

Sound Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Suven Life Sciences Ltd

Syntropharma Ltd

Takeda Pharmaceutical Co Ltd

Trevena Inc

VistaGen Therapeutics Inc

Yungjin Pharm Co Ltd

Zysis Ltd

Table of Contents

Table of Contents

Introduction

Depression - Overview

Depression - Therapeutics Development

Depression - Therapeutics Assessment

Depression - Companies Involved in Therapeutics Development

Depression - Drug ...

Table of Contents

Introduction

Depression - Overview

Depression - Therapeutics Development

Depression - Therapeutics Assessment

Depression - Companies Involved in Therapeutics Development

Depression - Drug Profiles

Depression - Dormant Projects

Depression - Discontinued Products

Depression - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Depression, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Depression, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Adamed Sp zoo, H1 2019

Depression - Pipeline by Addex Therapeutics Ltd, H1 2019

Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Alkermes Plc, H1 2019

Depression - Pipeline by Allergan Plc, H1 2019

Depression - Pipeline by Amorsa Therapeutics Inc, H1 2019

Depression - Pipeline by Anavex Life Sciences Corp, H1 2019

Depression - Pipeline by Angelini Group, H1 2019

Depression - Pipeline by Atai Life Sciences AG, H1 2019

Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Axsome Therapeutics Inc, H1 2019

Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Bionomics Ltd, H1 2019

Depression - Pipeline by BioXcel Therapeutics Inc, H1 2019

Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2019

Depression - Pipeline by Bristol-Myers Squibb Co, H1 2019

Depression - Pipeline by Calico LLC, H1 2019

Depression - Pipeline by Celgene Corp, H1 2019

Depression - Pipeline by Cellix Bio Pvt Ltd, H1 2019

Depression - Pipeline by Celon Pharma SA, H1 2019

Depression - Pipeline by Cerecor Inc, H1 2019

Depression - Pipeline by Clera Inc, H1 2019

Depression - Pipeline by Clexio Biosciences Ltd, H1 2019

Depression - Pipeline by Delpor Inc, H1 2019

Depression - Pipeline by Denovo Biopharma LLC, H1 2019

Depression - Pipeline by Douglas Pharmaceuticals Ltd, H1 2019

Depression - Pipeline by Eisai Co Ltd, H1 2019

Depression - Pipeline by Eli Lilly and Co, H1 2019

Depression - Dormant Projects, H1 2019

Depression - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Depression, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Figures

Number of Products under Development for Depression, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports